Home
Service
Physicians
Curriculum Vitae
Location
Retina Resources
Contact Us
 


James Su, M.D.YU-TANG JAMES SU, M.D.


Specialty:  Board certified in Ophthalmology with fellowship training in disease and surgery of retina & vitreous

Special interest in medical and surgical management of diabetic retinopathy, macular degeneration, retinal vascular disorder, macular pucker, macular hole, and retinal detachment.

Academic History:

1984 – 1989             The University of Texas at Arlington

                                    Arlington, Texas

                                    Graduated, June 1989

                                    Bachelor of Science in Biology

1989 – 1993             The University of Texas Medical School at Houston

                                    Houston, Texas

                                    Graduated, June 1993

                                    Doctor of Medicine

                                   *Outstanding Achievement in Ophth. Research Program

1993 – 1994             Saint Joseph Hospital Department of General Surgery

                                    Houston, Texas

                                    General Surgery Internship

                                   *Intern of the Year 

1995-1998               University of Maryland Department of Ophthalmology

                                    Baltimore, Maryland

                                    Resident in Ophthalmology

                                   *Chief Resident

1998-2002               Charles A. Garcia, MD and Assoc,Maurice B. Landers III, MD

                                    Saint Joseph Hospital, Retina Vascular Center

                                    Houston, Texas

                                    Retina Fellowship (98-00) Retina Associate (00-02)

2002-2006               Victoria Eye Center

                                    Victoria, Texas

2006-2008               Valley Retina Institute

                                    McAllen, Texas

2008-Present           Valley Vitreoretinal Consultants

                                    McAllen, Texas

 

Guest Speaker:      Management of Ocular injury in the ER setting

                              Diabetic retinopathy: Diagnosis and treatment

                              The aging eyes

Publications:  Su, J.; Garcia, C.A. M.D.; Chu, H.H. M.D.; “Retinal Pigmented Epithelium Transplantation” University of Texas Medical School Research Abstract. p.29, 1990

Su, J. M.D.; Steidl, S. M.D.; Liu, S. M.D.; Gupta, P. M.D.; “Inhibition of Intraocular Fibrin Formation During Vitrectomy Following Infusion of Desmopressin” ARVO, 1997

Liu, S. M.D.; Su, J. M.D.; Hemady, R. M.D.; “ Corneal Melting after Avulsion of a Molteno Shunt Plate” J. Glaucoma, Vol 6, No. 6: 357-358, 1997

Liu, S. M.D.; Su, J. M.D.; Steidl, S. M.D.; Gupta, P. M.D.; “Inhibition of Postvitrectomy Fibrin Using Troxerutin”  Retina, Vol 18, No. 3, 1998

Clinical Research: Sub-Investigator – A Phase 3 B, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Comparative Trial, In Parallel Groups, To Compare The Safety and Efficacy of Intravitreous Injections of Macugen Given Every 6 Weeks For 54 Weeks (To Be Extended To 102 Weeks As Indicated) Plus Sham Photodynamic Therapy (PDT), To Macugen Plus PDT With Visudyne, In Subjects With Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Protocol EOP1012. Version Date 28 August 2006. Study Closed.
 
Sub-Investigator – A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel of Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.003mg Pegaptanib Sodium (Macugen), Given as often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula. Protocol EOP1013. Version Date 11 December 2006. Study Closed.

Sub-Investigator – A Phase IV, Open-label, Multi-center Trial of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects with Subfoveal Neovascular Age-related Macular Degeneration (AMD) Initially Treated with a Different Modality Resulting in Maculopathy Improvement. Protocol EOP1023. Version Date 22 May 2006.

Sub-Investigator –A Trial to Assess the safety and Tolerability of repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects with Neovascular Age-Related Macular Degeneration. Protocol VGFT-OD-0603.

Sub-Investigator–A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Protocol FVF4170g.

Sub-Investigator – A Phase 3 B, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Protocol FVF3689g. Version Date 16 February 2006. Study Closed.

Sub-Investigator – A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy and ASI-001A 0.5 μg/day and ASI-001B 0.2 μg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema. Protocol C-01-05-001.Version Date 5 March 2007. Enrollment Closed.

Sub-Investigator – A Mutlicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel-Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial. Protocol TG-MV-003. Version Date 16 May 2007.

Sub- Investigator-A Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion.  Version 3.1. Dated 26 October 2005. Enrollment Closed

Sub- Investigator- A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up to 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME). Protocol Number 206207-012-00.

Sub- Investigator- A Phase 1 single ascending dose trial to establish the safety, tolerability and pharmacokinetic profile of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis® 0.5 mg/eye in subjects with neovascular age-related macular degeneration. Protocol OPH1000.

Sub- Investigator – A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects with Diffuse Diabetic Macular Edema. 2006-007-01-DME. Active.

Principal Investigator – Injectable Ophthalmic Emulsion For Use in the Treatment of Macular Edema a Phase I, Open-label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy.

Licensed:                 Texas and Maryland

Certification:          Board Certified: American Board of Ophthalmology

Organizations:       Fellow of American Academy of Ophthalmology

                              Member of American Society of Retina Specialist

                              Member of Texas Medical Association

                              Member of Texas Ophthalmological Association

Top